SUPPLEMENTARY FIGURE LEGENDS

Figure S1. Analysis of c-PB10. (A) Coomassie blue stained non-reduced SDS PAGE of cPB10 (lanes 4-7) as compared to a Mark 12 standard (lane 1) and Rituximab (lane 2). Lane 4 was loaded with 0.75 ug of protein and lanes 5-7 loaded in triplicate with 1.5 ug of protein. Data indicate cPB10 was successfully purified from *N. benthamiana* as an intact antibody with comparable purity to commercially derived Rituximab. Data was captured using a NuPAGE® Novex® 4-12% Bis-Tris gel. (B) HPLC Size Exclusion analysis of final cPB10 drug product. Data indicate that cPB10 was purified to 100% monomeric IgG. Data was captured using a TSKgel G3000SW from Tosoh Bioscience.

Figure S2. Subunit specificity of chimeric mAbs. Nunc Maxisorb F96 microtiter plates (ThermoFisher Scientific) were coated with ricin, RTA, RTB or BSA (each at 1 µg/ml) overnight and then probed with (**A**) c-SyH7 (**B**) c-PB10, (**C**) c-SylH3 or (**D**) c-JB4. Horseradish peroxidase (HRP)-labeled goat anti-human IgG (Invitrogen) was used as the secondary reagent and the plates were developed using 3,3',5,5' tetramethylbenzidine (Kirkegaard & Perry Labs, Gaithersburg, MD). The plates were analyzed with a SpectroMax 250 spectrophotometer with Softmax Pro 5.4.5 software (Molecular Devices, Sunnyvale, CA).